메뉴 건너뛰기




Volumn 367, Issue 22, 2012, Pages 2148-2149

Ponatinib for chronic myeloid leukemia

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; CD135 ANTIGEN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IMATINIB; PONATINIB;

EID: 84869986954     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe1210796     Document Type: Editorial
Times cited : (28)

References (8)
  • 1
    • 0029947186 scopus 로고    scopus 로고
    • Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells
    • Druker BJ, Tamura S, Buchduner E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
    • (1996) Nat Med , vol.2 , pp. 561-566
    • Druker, B.J.1    Tamura, S.2    Buchduner, E.3
  • 2
    • 0035800507 scopus 로고    scopus 로고
    • Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification
    • DOI 10.1126/science.1062538
    • Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80. (Pubitemid 32743979)
    • (2001) Science , vol.293 , Issue.5531 , pp. 876-880
    • Gorre, M.E.1    Mohammed, M.2    Ellwood, K.3    Hsu, N.4    Paquette, R.5    Nagesh, R.P.6    Sawyers, C.L.7
  • 3
    • 54349089682 scopus 로고    scopus 로고
    • Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression
    • Khorashad JS, de Lavallade H, Apperley JF, et al. Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression. J Clin Oncol 2008;26:4806-13.
    • (2008) J Clin Oncol , vol.26 , pp. 4806-4813
    • Khorashad, J.S.1    De Lavallade, H.2    Apperley, J.F.3
  • 4
    • 77953790762 scopus 로고    scopus 로고
    • Discovery of 3-[2-(imidazo[1,2b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4- [(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant
    • Huang W-S, Metcalf CA, Sundaramoorthi R, et al. Discovery of 3-[2-(imidazo[1,2b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1- yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant. J Med Chem 2010;53:4701-19.
    • (2010) J Med Chem , vol.53 , pp. 4701-4719
    • Huang, W.-S.1    Metcalf, C.A.2    Sundaramoorthi, R.3
  • 5
    • 70350507997 scopus 로고    scopus 로고
    • AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance
    • O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell 2009;16:401-12.
    • (2009) Cancer Cell , vol.16 , pp. 401-412
    • O'Hare, T.1    Shakespeare, W.C.2    Zhu, X.3
  • 6
    • 84870012939 scopus 로고    scopus 로고
    • Ponatinib in refractory Philadelphia chromosome - Positive leukemias
    • Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome - positive leukemias. N Engl J Med 2012;367:2075-88.
    • (2012) N Engl J Med , vol.367 , pp. 2075-2088
    • Cortes, J.E.1    Kantarjian, H.2    Shah, N.P.3
  • 7
    • 85031175535 scopus 로고    scopus 로고
    • PACE: A pivotal phase 2 trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315 mutation
    • Presented at the abstract
    • Cortes JE, Kim D-W, Pinilla-Ibarz J, et al. PACE: a pivotal phase 2 trial of ponatinib in patients with CML and Ph+ALL resistant or intolerant to dasatinib or nilotinib, or with the T315 mutation. Presented at the 17th Congress of the European Hematology Association, Amsterdam, June 14-17, 2012. abstract.
    • 17th Congress of the European Hematology Association, Amsterdam, June 14-17, 2012
    • Cortes, J.E.1    Kim, D.-W.2    Pinilla-Ibarz, J.3
  • 8
    • 79958760963 scopus 로고    scopus 로고
    • Potent activity of ponatinib in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies
    • Gozgit JM, Wong MJ, Wardwell S, et al. Potent activity of ponatinib in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther 2011;10:1028-35.
    • (2011) Mol Cancer Ther , vol.10 , pp. 1028-1035
    • Gozgit, J.M.1    Wong, M.J.2    Wardwell, S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.